BioBehavioral Diagnostics
BioBehavioral Diagnostics' (BioBDx) mission is to develop, manufacture, and market proprietary diagnostic systems for the quantitative assessment of behavioral disorders, including the measurement of medication
response and the prediction of therapeutic efficacy for a patient.
The company’s lead product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity Disorder (MMAT/ADHD™ System), is designed to enable clinicians to accurately diagnose ADHD, select the right class of medication, and measure therapeutic efficacy of a given drug. The MMAT/ADHD™ System is currently FDA approved as an aid for the diagnosis of ADHD. The company anticipates a product launch early in 2008.